Opthea presents Wet AMD data at Macula Society Meet
Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...
FDA approves Susvimo for diabetic macular edema
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...
Opthea Wet AMD Data Featured at Macula Society Meeting
Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...
New Atlas13h
Ozempic is suspected in more cases of sudden vision loss
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Pharmabiz16h
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
PharmiWeb1d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Business Wire2d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
bjo.bmj3d
High-sensitivity C-reactive protein and risk of retinal artery occlusion and ischaemic stroke: a cross-cohort study
Aims Previous studies have suggested an association between retinal artery occlusion (RAO) and ischaemic stroke (IS), both associated with elevated inflammatory factors. However, the role of ...